News & Videos - REGULUS THERAPEUTICS INC. - Page 2

Regulus Therapeutics Advances to Cohort 2 of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) PR Newswire SAN DIEGO, May 16, 2023 Blinded safety data observed so far are encouraging SAN DIEGO , May 16, 2023 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"),...

Regulus Therapeutics Reports First Quarter 2023 Financial Results and Recent Updates PR Newswire SAN DIEGO, May 11, 2023 Enrollment completed in first cohort of patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD) in Phase 1b Multiple-Ascending Dose (MAD) study of RGLS8429 Closed $15.0 million private placement of equity; expected to extend cash runway into mid-2024 SAN DIEGO , May 11, 2023 /PRNewswire/ -- Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company...

Regulus Therapeutics Announces $15 Million Private Placement of Equity PR Newswire SAN DIEGO, April 13, 2023 SAN DIEGO , April 13, 2023 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced that it has entered into a definitive securities purchase agreement in connection with a private placement to certain institutional investors and...

Regulus Therapeutics Announces Completion of Enrollment in First Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD) PR Newswire SAN DIEGO, April 12, 2023 SAN DIEGO , April 12, 2023 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today...

Regulus Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Recent Updates PR Newswire SAN DIEGO, March 23, 2023 Enrollment progressing in Phase 1b Multiple-Ascending Dose (MAD) study of RGLS8429 in patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD) Top-line data in the first cohort of RGLS8429-treated ADPKD patients anticipated in second half of 2023 Expansion of team with key leadership appointments in clinical development, regulatory and clinical...

Regulus Therapeutics to Present at the SVB Securities Global Biopharma Conference PR Newswire SAN DIEGO, Feb. 9, 2023 SAN DIEGO , Feb. 9, 2023 /PRNewswire/ -- Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced that Jay Hagan , President and Chief Executive Officer of Regulus, will present at the SVB Securities Global Biopharma Conference on...

Regulus Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) PR Newswire SAN DIEGO, Jan. 13, 2023 SAN DIEGO , Jan. 13, 2023 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced the grant of an inducement stock option to Claire Padgett , Ph.D. and to Rekha Garg , M.D., M.S., on January 11, 2023 in connection with their...

Regulus Therapeutics Announces Resignation of Board Member PR Newswire SAN DIEGO, Dec. 12, 2022 SAN DIEGO , Dec. 12, 2022 /PRNewswire/ -- Regulus Therapeutics Inc . ( Nasdaq : RGLS ), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or " Regulus "), today announced that Simos Simeonidis , Ph .D., member of the Board of Directors, has stepped down from the Board, due to the time requirements of his recent appointment...

Regulus Therapeutics Announces Appointments of Industry Veterans, Drs. Rekha Garg and Claire Padgett, to Lead Clinical Development, Regulatory and Clinical Operations PR Newswire SAN DIEGO, Nov. 29, 2022 Additional Preclinical Promotions Round Out Scientific Leadership SAN DIEGO , Nov. 29, 2022 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"),...

Regulus Therapeutics Reports Third Quarter 2022 Financial Results and Recent Updates PR Newswire SAN DIEGO, Nov. 10, 2022 Company announced first patient dosed in its Phase 1b Multiple-Ascending Dose (MAD) study of RGLS8429 in patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD) Company announced positive topline safety and pharmacokinetic (PK) data from its Phase 1 Single-Ascending Dose (SAD) study of RGLS8429 in healthy volunteers for the treatment of ADPKD $4.5 million in net...

Regulus Therapeutics Announces Timing for Third Quarter 2022 Financial Results Webcast and Conference Call PR Newswire SAN DIEGO, Nov. 3, 2022 SAN DIEGO , Nov. 3, 2022 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced that it will report its third quarter 2022 financial results on Thursday, November 10, 2022 , after the U.S....

Regulus Therapeutics Announces First Patient Dosed in Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) PR Newswire SAN DIEGO, Nov. 2, 2022 SAN DIEGO , Nov. 2, 2022 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced the dosing of the first...

Regulus Therapeutics Announces Poster Presentation at ASN Kidney Week 2022 PR Newswire SAN DIEGO, Oct. 27, 2022 SAN DIEGO , Oct. 27, 2022 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced a poster presentation at the American Society of Nephrology Kidney Week 2022 ( ASN Kidney Week 2022 ), which will take place in Orlando, November...

Regulus Therapeutics Announces Positive Topline Safety and Pharmacokinetic (PK) Data from the Phase 1 Single-Ascending Dose (SAD) Clinical Trial of RGLS8429 for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) PR Newswire SAN DIEGO, Sept. 12, 2022 Phase 1b Multiple Ascending Dose (MAD) Study Initiated RGLS8429 in healthy volunteers was well-tolerated with dose-proportional PK Topline data from first cohort of patients with ADPKD anticipated in 1H 2023 SAN DIEGO , Sept. 12,...

Regulus Therapeutics to Participate in Upcoming Investor Conferences PR Newswire SAN DIEGO, Sept. 2, 2022 SAN DIEGO , Sept. 2, 2022 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced that the Company will participate in two upcoming investor conferences. Details are as follows: Wells Fargo Healthcare Conference taking place...

Regulus Therapeutics Reports Second Quarter 2022 Financial Results and Recent Updates PR Newswire SAN DIEGO, Aug. 11, 2022 IND accepted and first subject dosed in the Phase 1 Single-Ascending Dose (SAD) study of RGLS8429 for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) RGLS8429 granted Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA) Scientific leadership strengthened with the appointment of Amin Kamel , Ph.D., as Vice President, Drug...

Regulus Therapeutics Announces Timing for Second Quarter 2022 Financial Results Webcast and Conference Call PR Newswire SAN DIEGO, Aug. 4, 2022 SAN DIEGO , Aug. 4, 2022 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced that it will report its second quarter 2022 financial results on Thursday, August 11, 2022 , after the U.S....

Regulus Therapeutics Announces Receipt of FDA Orphan Drug Designation for RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) PR Newswire SAN DIEGO, June 21, 2022 SAN DIEGO , June 21, 2022 /PRNewswire/ -- Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced that the U.S. Food and Drug Administration (FDA) has granted...

Regulus Therapeutics Announces First Subject Dosed in Phase 1 Single-Ascending Dose (SAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) PR Newswire SAN DIEGO, June 13, 2022 SAN DIEGO , June 13, 2022 /PRNewswire/ -- Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced the dosing of the first...

Regulus Appoints Amin Kamel, Ph.D., as Vice President, DMPK PR Newswire SAN DIEGO, June 2, 2022 SAN DIEGO , June 2, 2022 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced the appointment of Amin Kamel , Ph.D., as Vice President, DMPK. In his role, Dr. Kamel will support clinical development, in particular advancement of the...